Keytruda涓绾挎不灏虹

濂芥榛娌涓PD-1娉拌KEYTRUDAFDA瑰锛ㄤ不PD-L1楂琛ㄨ揪锛TPS>50%锛杞Щч灏虹ｈ虹ｈ浜涔澶娌荤伴╁

涓鸿村涓藉ぇ跨ゆｈ浜ㄧ椤跺璇娈靛ㄧ姝ョ拌锛荤宸插璧存腐婢冲氨绘￠」甯ｈ瀵规璧娣辩娓境跨や绉诲锛瀵逛ｈ锛 浠ラ杩娓境诲蹇风拌╃娌荤濡ㄥ璇ユ℃磋叮锛寸佃400-005-9900娣诲ュ悍椤鹃井淇″锛medtaphr锛锛涓涓诲㈤灏涓烘ㄨ缁浠缁稿虫°涓虹戒堕达ㄦ娈靛府╂ｈ垫剧

褰版堕1024ワ榛娌涓瀹ｅ锛剁PD-1娉拌KEYTRUDA寰FDA瑰锛ㄤ不PD-L1楂琛ㄨ揪锛TPS>50%锛杞Щч灏虹ｈ杩浣垮KEYTRUDA涓虹圭涓绾挎不灏虹锛NSCLC锛PD-1娉

KEYTRUDA逛富瑕轰KEYNOTE-024恒寮俱III涓村璇楠版KEYNOTE-024绌舵杈浜Keytruda不涓绫昏╁瀵硅浆绉绘ч讹18%锛槌讹82%锛NSCLC娌荤绌舵浜305渚㈠杩绯荤涓哄甫EGFRALK绐PD-L1楂琛ㄨ揪锛TPS50%锛NSCLCｈ锛虹浜Keytruda 锛200mg姣31娆★锛圭插+￠锛圭插+椤洪锛瑗夸婊+椤洪锛瑗夸婊+￠绱+￠锛绌剁涓昏缁规杩灞瀛锛PFS锛锛朵缁逛负荤瀛锛OS锛绘锛ORR锛

缁琛ㄦ涓告锛浣跨KEYTRUDAｈ杩灞瀛(HR, 0.50 [95% CI, 0.37, 0.68]; p<0.001)涓讳瀛(HR, 0.60 [95% CI, 0.41, 0.89]; p=0.005)藉颁捐瑰

KEYNOTE-024浼绉涓村璇楠版ユ锛榛娌涓瀹缃锛

姝ゆKeytruda规涓洪涓逛绾挎不NSCLCPD-1锛崇ｈㄨ璇负虹浠ュ浜涔澶娌荤伴╋涓杩瀵PD-L1琛ㄨ揪姘村钩EGFRALK绐舵瑕姹锛姝や复搴荤瑕寮哄瀛璁扮╂娴芥澶х搴Keytruda涓村娌荤

淇℃锛

FDA Approves Mercks KEYTRUDA? (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations. Merck & Co., October 24, 2016.